Navigate Up
UPMC/University of Pittsburgh Schools of the Health Sciences
Manager
Telephone: 412-864-4151

Patients and medical professionals may call 1-800-533-UPMC (8762) for more information.
 

Patients and medical professionals may call 1-800-533-UPMC (8762) for more information.
 

 

Starzl Transplant Institute Researchers Receive NIH Grant to Develop Promising Cell-Based Strategy for Transplant Tolerance

PITTSBURGH, October 16, 2002 — Researchers from the University of Pittsburgh’s Thomas E. Starzl Transplantation Institute have been awarded $2.3 million from the National Institute of Allergy and Infectious Diseases to explore whether a special type of immune system cell can help induce immune tolerance in kidney transplantation.

Specifically, the researchers will try to harness a subset of dendritic cells that have unique tolerance-enhancing qualities to see whether the cells can be directed to influence the acceptance of transplanted donor kidneys, including kidneys that are immunologically mismatched to the recipient. The studies, which will focus on nonhuman primates, are based on other animal research and evidence in transplant patients successfully weaned off all immunosuppression that show a subpopulation of dendritic cells might play a key role in convincing the immune system to accept a transplanted organ.

“We are hopeful that a clinical strategy to induce tolerance in transplant patients will emerge from these studies in nonhuman primates. Indeed, it is everyone’s goal working in the field of transplantation to identify ways to promote the permanent, drug-free acceptance of transplanted organs,” said the study’s principal investigator, Angus W. Thomson, Ph.D., D.Sc., professor of surgery and immunology at the Thomas E. Starzl Transplantation Institute and the University of Pittsburgh School of Medicine.

The grant builds on several findings that have been reported in recent years by Dr. Thomson and members of his research team. In one set of studies, a pre-transplant infusion of these dendritic cell subtypes, which derive from lymphoid tissue or blood, allowed for prolonged survival in a mouse heart transplant model, even without the use of drugs to control rejection. In contrast, the better-known myeloid dendritic cells accelerated the rejection response.

According to the researchers, transplant patients who are off immunosuppression have fewer of these type of dendritic cells normally associated with rejection than transplant patients who are prone to rejection or who rely on anti-rejection drugs to maintain their transplanted organ. They also appear to have more of the “good” dendritic cells, according to the Pitt researchers.

Dendritic cells, a rare type of white blood cell that is present in all tissues, are known for their ability to identify and present antigens, or foreign substances, to other immune system cells that are programmed to destroy the antigen. Until recently, they have been thought only to be involved in prompting the rejection process. But the subtype of dendritic cells apparently has the opposite effect by regulating the immune response and determining that a frontline attack against the organ by T cells is unwarranted. T cells are the soldiers for the immune system that take their cue from other key cells.

Working with Dr. Thomson on the five-year grant are the following co-investigators from the University of Pittsburgh: Patrick T. Coates, M.D., Ph.D.; Simon M. Barratt-Boyes, D.V.M., Ph.D.; Adrian E. Morelli, M.D., Ph.D.; Albert D. Donnenberg, Ph.D.; Michael A. Murphy-Corb, Ph.D.; and Anita M. Trichel, D.V.M. Christian P. Larsen, M.D., D. Phil, and Thomas C. Pearson, M.D., D.Phil, from Emory University and Yerkes Primate Research Center in Atlanta, are co-investigators as well.

©  UPMC | Affiliated with the University of Pittsburgh Schools of the Health Sciences
Supplemental content provided by A.D.A.M. Health Solutions. All rights reserved.

For help in finding a doctor or health service that suits your needs, call the UPMC Referral Service at 412-647-UPMC (8762) or 1-800-533-UPMC (8762). Select option 1.

UPMC is an equal opportunity employer. UPMC policy prohibits discrimination or harassment on the basis of race, color, religion, ancestry, national origin, age, sex, genetics, sexual orientation, marital status, familial status, disability, veteran status, or any other legally protected group status. Further, UPMC will continue to support and promote equal employment opportunity, human dignity, and racial, ethnic, and cultural diversity. This policy applies to admissions, employment, and access to and treatment in UPMC programs and activities. This commitment is made by UPMC in accordance with federal, state, and/or local laws and regulations.

Medical information made available on UPMC.com is not intended to be used as a substitute for professional medical advice, diagnosis, or treatment. You should not rely entirely on this information for your health care needs. Ask your own doctor or health care provider any specific medical questions that you have. Further, UPMC.com is not a tool to be used in the case of an emergency. If an emergency arises, you should seek appropriate emergency medical services.

For UPMC Mercy Patients: As a Catholic hospital, UPMC Mercy abides by the Ethical and Religious Directives for Catholic Health Care Services, as determined by the United States Conference of Catholic Bishops. As such, UPMC Mercy neither endorses nor provides medical practices and/or procedures that contradict the moral teachings of the Roman Catholic Church.

© UPMC
Pittsburgh, PA, USA UPMC.com